Yasim Alptekin, Eroglu Erdinc, Bozoglan Orhan, Mese Bulent, Acipayam Mehmet, Kara Hakan
1 Department of Cardiovascular Surgery, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
2 Department of Cardiovascular Surgery, Giresun Ada Hospital, Giresun, Turkey.
Phlebology. 2017 Apr;32(3):194-199. doi: 10.1177/0268355516638577. Epub 2016 Jul 9.
Objective This report aims to present the early results of a retrospective study of the use of N-butyl cyanoacrylate (VariClose®)-based non-tumescent endovenous ablation for the treatment of patients with varicose veins. Method One hundred and eighty patients with varicose veins due to incompetent saphenous veins were treated with the VariClose® endovenous ablation method between May 2014 and November 2014. The patient sample consisted of 86 men and 94 women, with a mean age of 47.7 ± 11.7 years. The patients had a great saphenous vein diameter greater than 5.5 mm and a small saphenous vein diameter greater than 4 mm in conjunction with reflux for more than 0.5 s. Patients with varicose veins were evaluated with venous duplex examination, Clinical, Etiological, Anatomical and Pathophysiological classification (CEAP), and their Venous Clinical Severity Scores were recorded. Results The median CEAP score of patients was three, and the saphenous vein diameters were between 5.5 and 14 mm (mean of 7.7 ± 2.1 mm). A percutaneous entry was made under local anesthesia to the great saphenous vein in 169 patients and to the small saphenous vein in 11 patients. Duplex examination immediately after the procedure showed closure of the treated vein in 100% of the treated segment. No complications were observed. The mean follow-up time was 5.5 months (ranging from three to seven months). Recanalization was not observed in any of the patients during follow-up. The average Venous Clinical Severity Scores was 10.2 before the procedure and decreased to 3.9 after three months (p < 0.001). Conclusion The application of N-butyl cyanoacrylate (VariClose®) is an effective method for treating varicose veins; it yielded a high endovenous closure rate, with no need for tumescent anesthesia. However, long-term results are currently unknown.
目的 本报告旨在呈现一项回顾性研究的早期结果，该研究使用基于氰基丙烯酸正丁酯（VariClose®）的非肿胀性静脉内消融术治疗静脉曲张患者。方法 2014年5月至2014年11月期间，180例因隐静脉功能不全导致静脉曲张的患者接受了VariClose®静脉内消融术治疗。患者样本包括86名男性和94名女性，平均年龄为47.7±11.7岁。患者大隐静脉直径大于5.5mm，小隐静脉直径大于4mm，且伴有反流超过0.5秒。对静脉曲张患者进行静脉双功超声检查、临床、病因、解剖和病理生理分类（CEAP），并记录其静脉临床严重程度评分。结果 患者的CEAP评分中位数为3分，隐静脉直径在5.5至14mm之间（平均为7.7±2.1mm）。169例患者在局部麻醉下经皮穿刺进入大隐静脉，11例患者进入小隐静脉。术后立即进行的双功超声检查显示，100%的治疗节段内治疗静脉闭合。未观察到并发症。平均随访时间为5.5个月（范围为3至7个月）。随访期间未观察到任何患者出现再通。术前平均静脉临床严重程度评分为10.2分，术后3个月降至3.9分（p<0.001）。结论 氰基丙烯酸正丁酯（VariClose®）的应用是治疗静脉曲张的有效方法；它实现了较高的静脉内闭合率，无需肿胀麻醉。然而，目前尚不清楚长期结果。
